MRKR earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.85. Updated 2026-07-23.
Marker Therapeutics (MRKR) Research Hub
Marker Therapeutics (MRKR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.15 USD (-4.96%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.85, market cap 0.01B. This hub links to the full technical, earnings and options research available for MRKR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.15 USD (-4.96%) |
| 52-week range | 1.05 USD – 1.72 USD |
| Trend regime | Range |
| 14-day RSI | 51.5 (Neutral) |
| Trailing P/E | -1.85 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for MRKR
Covered Call on MRKR: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MRKR: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MRKR: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
MRKR technical analysis: range, last 1.15 USD, RSI 51.5, 52w range 1.05 USD–1.72 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MRKR in?
Marker Therapeutics (MRKR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MRKR in an uptrend or downtrend?
As of 2026-09-11, MRKR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MRKR's trailing P/E ratio?
MRKR's trailing P/E is -1.85, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does MRKR next report earnings?
MRKR is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.25 USD.